Molecular and Translational Vascular Medicine 2012th Edition

From the reviews:

“It is designed to be a source for translational vascular medicine research. The book is intended for physicians, residents, fellows, and graduate students from a variety of different specialties related to vascular disease. … This is a unique compilation of topics that would be valuable to both physicians and researchers, with the common interest being vascular disease. It is well written and carefully thought out. It is a welcome addition to the literature and fills an obvious void in existing publications.” (Melina Kibbe, Doody’s Review Service, March, 2013)

Molecular and Translational Vascular Medicine 2012th Edition will serve as a state-of-the-art resource for physicians and translational medical researchers alike who are interested in the rapidly evolving field of vascular medicine. The text provides new insight into the basic mechanisms of classic vascular pathophysiologic processes like angiogenesis, atherosclerosis, thrombosis, and vasculitis. Furthermore, it covers new areas of investigation including the role of the ubiquitin proteasome system in vascular disease, endothelial progenitor cells for disease treatment, and the genetic basis of thoracic aortic aneurysms. Lastly, this volume includes sections on the newly emerging field of therapeutic angiogenesis, and the developing technology of nanoparticle-based imaging and therapeutic treatment of the diseased vasculature. All chapters are written by established experts in their fields, including pathologists, cardiovascular surgeons, and internists as well as translational biomedical researchers in a wide range of disciplines. While comprehensive, the material is presented in a manner that simplifies the complex pathophysiologic mechanisms that underlie common vascular diseases.

Molecular and Translational Vascular Medicine 2012th Edition will be of great value to a broad audience including internists, cardiovascular and vascular surgeons, pathologists, residents and fellows, as well as translational biomedical researchers.